GEA, a global systems supplier for the pharmaceuticals, has progressed the industry’s ability to conduct more flexible, continuous processing with its novel technology: ConsiGma® CDC flex.
To dispel the common myths that #GoingConti is overly complex and expensive, Hovione and GEA Pharma & Healthcare recently announced an industry first collaboration that holds great promise for the pharmaceutical manufacturing sector.
Bringing continuous to the forefront
Together, the two companies aim to significantly increase the adoption of continuous manufacturing by providing enhanced capacity, flexibility, standardised equipment, improved quality and increased efficiency.
At the time of the announcement, GEA Pharma & Healthcare’s Phillip Gabb, Strategic Business Director, Pharma Solid Dosage, noted: “Continuous manufacturing systems allow for leaner and risk-reduced development paths, leaner supply chains, increased built-in quality and — in general — manufacturing processes that are more flexible and less complex. In the context of this strategic collaboration, Hovione and GEA will combine their strengths to further advance the technology and contribute to the establishment of higher standards and new levels of market acceptance.”
ConsiGma
To achieve optimal continuous manufacturing, GEA has developed ConsiGma CDC flex, which has been designed to operate in both continuous and batch modes, offering both high and low throughput functionality.
With a focus on user-friendliness, the ConsiGma range will be further augmented with new developments to simplify routine operations, introduce automated workflows and Smart control interfaces.
This will empower operators to streamline production processes.
“We believe that continuous tableting can offer significant benefits to our customers, not
only by expediting time-to-market and reducing development and manufacturing costs but also by improving product quality and sustainability,” commented Filipe Gaspar, Vice President of Technology Intensification at Hovione. “Through our collaboration with GEA, we aim to revolutionise the continuous production of oral solid dosage forms, making the technology more accessible and efficient for pharma customers.”
